Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 431

1.

Japanese guideline for the treatment of idiopathic pulmonary fibrosis.

Homma S, Bando M, Azuma A, Sakamoto S, Sugino K, Ishii Y, Izumi S, Inase N, Inoue Y, Ebina M, Ogura T, Kishi K, Kishaba T, Kido T, Gemma A, Goto Y, Sasaki S, Johkoh T, Suda T, Takahashi K, Takahashi H, Taguchi Y, Date H, Taniguchi H, Nakayama T, Nishioka Y, Hasegawa Y, Hattori N, Fukuoka J, Miyamoto A, Mukae H, Yokoyama A, Yoshino I, Watanabe K; Ministry of Health, Labour and Welfare, the Study Group on Diffuse Pulmonary Disorders, Scientific Research/Research on Intractable Diseases, and Japanese Respiratory Society.

Respir Investig. 2018 Jul;56(4):268-291. doi: 10.1016/j.resinv.2018.03.003. Epub 2018 Jul 3. Review.

PMID:
29980444
2.

Prognostic significance of ventricular late potentials in patients with pulmonary sarcoidosis.

Yodogawa K, Seino Y, Ohara T, Iwasaki YK, Hayashi M, Miyauchi Y, Azuma A, Shimizu W.

Heart Rhythm. 2018 Jun;15(6):798-802. doi: 10.1016/j.hrthm.2018.03.013.

PMID:
29857850
3.

Resolution of bleomycin-induced murine pulmonary fibrosis via a splenic lymphocyte subpopulation.

Kamio K, Azuma A, Matsuda K, Usuki J, Inomata M, Morinaga A, Kashiwada T, Nishijima N, Itakura S, Kokuho N, Atsumi K, Hayashi H, Yamaguchi T, Fujita K, Saito Y, Abe S, Kubota K, Gemma A.

Respir Res. 2018 Apr 24;19(1):71. doi: 10.1186/s12931-018-0783-2.

4.

A Community-Level Initiative to Prevent Obesity: Results From Kaiser Permanente's Healthy Eating Active Living Zones Initiative in California.

Cheadle A, Atiedu A, Rauzon S, Schwartz PM, Keene L, Davoudi M, Spring R, Molina M, Lee L, Boyle K, Williamson D, Steimberg C, Tinajero R, Ravel J, Nudelman J, Azuma AM, Kuo ES, Solomon L.

Am J Prev Med. 2018 May;54(5S2):S150-S159. doi: 10.1016/j.amepre.2018.01.024.

5.

Reduced incidence of lung cancer in patients with idiopathic pulmonary fibrosis treated with pirfenidone.

Miura Y, Saito T, Tanaka T, Takoi H, Yatagai Y, Inomata M, Nei T, Saito Y, Gemma A, Azuma A.

Respir Investig. 2018 Jan;56(1):72-79. doi: 10.1016/j.resinv.2017.09.007. Epub 2017 Oct 25.

PMID:
29325685
6.

Prognostic Factors in the Acute Exacerbation of Idiopathic Pulmonary Fibrosis: A Retrospective Single-center Study.

Atsumi K, Saito Y, Kuse N, Kobayashi K, Tanaka T, Kashiwada T, Inomata M, Kokuho N, Hayashi H, Kamio K, Fujita K, Abe S, Azuma A, Kubota K, Gemma A.

Intern Med. 2018 Mar 1;57(5):655-661. doi: 10.2169/internalmedicine.9331-17. Epub 2017 Nov 20.

7.

CRISPR/Cas9-mediated targeted mutagenesis in grape.

Nakajima I, Ban Y, Azuma A, Onoue N, Moriguchi T, Yamamoto T, Toki S, Endo M.

PLoS One. 2017 May 18;12(5):e0177966. doi: 10.1371/journal.pone.0177966. eCollection 2017.

8.

Cyclic mechanical stretch-induced oxidative stress occurs via a NOX-dependent mechanism in type II alveolar epithelial cells.

Tanaka T, Saito Y, Matsuda K, Kamio K, Abe S, Kubota K, Azuma A, Gemma A.

Respir Physiol Neurobiol. 2017 Aug;242:108-116. doi: 10.1016/j.resp.2017.04.007. Epub 2017 Apr 22.

PMID:
28442445
9.

XPLN is modulated by HDAC inhibitors and negatively regulates SPARC expression by targeting mTORC2 in human lung fibroblasts.

Kamio K, Azuma A, Usuki J, Matsuda K, Inomata M, Nishijima N, Itakura S, Hayashi H, Kashiwada T, Kokuho N, Atsumi K, Yamaguchi T, Fujita K, Saito Y, Abe S, Kubota K, Gemma A.

Pulm Pharmacol Ther. 2017 Jun;44:61-69. doi: 10.1016/j.pupt.2017.03.003. Epub 2017 Mar 14.

PMID:
28315487
10.

Nrf2 Regulates the Risk of a Diesel Exhaust Inhalation-Induced Immune Response during Bleomycin Lung Injury and Fibrosis in Mice.

Li YJ, Shimizu T, Shinkai Y, Hirata Y, Inagaki H, Takeda K, Azuma A, Yamamoto M, Kawada T.

Int J Mol Sci. 2017 Mar 17;18(3). pii: E649. doi: 10.3390/ijms18030649.

11.

Safety management of treatment with nintedanib in clinical practice of IPF.

Azuma A.

Respir Investig. 2017 Jan;55(1):1. doi: 10.1016/j.resinv.2016.12.001. No abstract available.

12.

Nintedanib in Japanese patients with idiopathic pulmonary fibrosis: A subgroup analysis of the INPULSIS® randomized trials.

Azuma A, Taniguchi H, Inoue Y, Kondoh Y, Ogura T, Homma S, Fujimoto T, Sakamoto W, Sugiyama Y, Nukiwa T.

Respirology. 2017 May;22(4):750-757. doi: 10.1111/resp.12960. Epub 2016 Dec 20.

PMID:
27997064
13.

Idiopathic Pulmonary Fibrosis: Treatment and Prognosis.

Fujimoto H, Kobayashi T, Azuma A.

Clin Med Insights Circ Respir Pulm Med. 2016 Dec 8;9(Suppl 1):179-185. eCollection 2015. Review.

14.

An exploratory trial of intravenous immunoglobulin therapy for idiopathic pulmonary fibrosis: a preliminary multicenter report.

Enomoto N, Chida K, Suda T, Kaida Y, Taniguchi M, Azuma A, Hayashi H, Ogura T, Kitamura H, Yamaguchi O, Ando M, Sato A, Kudo S.

Clin Respir J. 2016 Nov;10(6):746-755. doi: 10.1111/crj.12281. Epub 2015 Mar 19.

PMID:
25689162
15.

Pirfenidone exerts a suppressive effect on CCL18 expression in U937-derived macrophages partly by inhibiting STAT6 phosphorylation.

Saito Y, Azuma A, Matsuda K, Kamio K, Abe S, Gemma A.

Immunopharmacol Immunotoxicol. 2016 Oct 27:1-8. [Epub ahead of print]

PMID:
27788604
16.

Long-term efficacy of macrolide treatment in idiopathic pulmonary fibrosis: a retrospective analysis.

Kuse N, Abe S, Hayashi H, Kamio K, Saito Y, Usuki J, Azuma A, Kudoh S, Gemma A.

Sarcoidosis Vasc Diffuse Lung Dis. 2016 Oct 7;33(3):242-246.

PMID:
27758989
17.

The photomorphogenic factors UV-B RECEPTOR 1, ELONGATED HYPOCOTYL 5, and HY5 HOMOLOGUE are part of the UV-B signalling pathway in grapevine and mediate flavonol accumulation in response to the environment.

Loyola R, Herrera D, Mas A, Wong DC, Höll J, Cavallini E, Amato A, Azuma A, Ziegler T, Aquea F, Castellarin SD, Bogs J, Tornielli GB, Peña-Neira A, Czemmel S, Alcalde JA, Matus JT, Arce-Johnson P.

J Exp Bot. 2016 Oct;67(18):5429-5445. Epub 2016 Aug 19.

18.

A phase II trial evaluating the efficacy and safety of perioperative pirfenidone for prevention of acute exacerbation of idiopathic pulmonary fibrosis in lung cancer patients undergoing pulmonary resection: West Japan Oncology Group 6711 L (PEOPLE Study).

Iwata T, Yoshino I, Yoshida S, Ikeda N, Tsuboi M, Asato Y, Katakami N, Sakamoto K, Yamashita Y, Okami J, Mitsudomi T, Yamashita M, Yokouchi H, Okubo K, Okada M, Takenoyama M, Chida M, Tomii K, Matsuura M, Azuma A, Iwasawa T, Kuwano K, Sakai S, Hiroshima K, Fukuoka J, Yoshimura K, Tada H, Nakagawa K, Nakanishi Y; West Japan Oncology Group.

Respir Res. 2016 Jul 22;17(1):90. doi: 10.1186/s12931-016-0398-4.

19.

Subgroup analysis of Asian patients in the INPULSIS® trials of nintedanib in idiopathic pulmonary fibrosis.

Taniguchi H, Xu Z, Azuma A, Inoue Y, Li H, Fujimoto T, Bailes Z, Schlenker-Herceg R, Kim DS.

Respirology. 2016 Nov;21(8):1425-1430. doi: 10.1111/resp.12852. Epub 2016 Jul 11.

20.

Context Dependent Effect of Landscape on the Occurrence of an Apex Predator across Different Climate Regions.

Fujita G, Azuma A, Nonaka J, Sakai Y, Sakai H, Iseki F, Itaya H, Fukasawa K, Miyashita T.

PLoS One. 2016 Apr 28;11(4):e0153722. doi: 10.1371/journal.pone.0153722. eCollection 2016.

21.

COPD advances in left ventricular diastolic dysfunction.

Kubota Y, Asai K, Murai K, Tsukada YT, Hayashi H, Saito Y, Azuma A, Gemma A, Shimizu W.

Int J Chron Obstruct Pulmon Dis. 2016 Mar 29;11:649-55. doi: 10.2147/COPD.S101082. eCollection 2016.

22.

Pulmonary mucosa-associated lymphoid tissue lymphoma associated with pulmonary sarcoidosis: a case report and literature review.

Kokuho N, Terasaki Y, Urushiyama H, Terasaki M, Kunugi S, Morimoto T, Azuma A, Usuda J, Gemma A, Eishi Y, Shimizu A.

Hum Pathol. 2016 May;51:57-63. doi: 10.1016/j.humpath.2015.12.019. Epub 2016 Jan 14. Review.

PMID:
27067783
23.

An efficient method for the preparation of preferentially heterodimerized recombinant S100A8/A9 coexpressed in Escherichia coli.

Futami J, Atago Y, Azuma A, Putranto EW, Kinoshita R, Murata H, Sakaguchi M.

Biochem Biophys Rep. 2016 Mar 19;6:94-100. doi: 10.1016/j.bbrep.2016.03.009. eCollection 2016 Jul.

24.

Clinical Experience of the Long-term Use of Pirfenidone for Idiopathic Pulmonary Fibrosis.

Bando M, Yamauchi H, Ogura T, Taniguchi H, Watanabe K, Azuma A, Homma S, Sugiyama Y; Japan Pirfenidone Clinical Study Group.

Intern Med. 2016;55(5):443-8. doi: 10.2169/internalmedicine.55.5272. Epub 2016 Mar 1.

25.

Variants near the HLA complex group 22 gene (HCG22) confer increased susceptibility to late-onset asthma in Japanese populations.

Yatagai Y, Hirota T, Sakamoto T, Yamada H, Masuko H, Kaneko Y, Iijima H, Naito T, Noguchi E, Tamari M, Kubo M, Takahashi A, Konno S, Makita H, Nishimura M, Hijikata M, Keicho N, Homma S, Taguchi Y, Azuma A, Kudoh S, Hizawa N.

J Allergy Clin Immunol. 2016 Jul;138(1):281-283.e13. doi: 10.1016/j.jaci.2015.11.023. Epub 2016 Jan 30. No abstract available.

PMID:
26830115
26.

Cyclosporine A combined with low-dose corticosteroid treatment in patients with idiopathic pulmonary fibrosis.

Miyazaki Y, Azuma A, Inase N, Taniguchi H, Ogura T, Inoue E, Takeuchi M, Yoshizawa Y, Sugiyama Y, Kudoh S; IPF trial group in Japan.

Respir Investig. 2015 Nov;53(6):288-95. doi: 10.1016/j.resinv.2015.05.002. Epub 2015 Jul 14.

PMID:
26521106
27.

Efficacy of pirfenidone and disease severity of idiopathic pulmonary fibrosis: Extended analysis of phase III trial in Japan.

Taguchi Y, Ebina M, Hashimoto S, Ogura T, Azuma A, Taniguchi H, Kondoh Y, Suga M, Takahashi H, Nakata K, Sugiyama Y, Kudoh S, Nukiwa T; Pirfenidone Clinical Study Group in Japan.

Respir Investig. 2015 Nov;53(6):279-87. doi: 10.1016/j.resinv.2015.06.002. Epub 2015 Oct 23.

PMID:
26521105
28.

Risk factors for acute exacerbation of idiopathic pulmonary fibrosis--Extended analysis of pirfenidone trial in Japan.

Kondoh Y, Taniguchi H, Ebina M, Azuma A, Ogura T, Taguchi Y, Suga M, Takahashi H, Nakata K, Sugiyama Y, Kudoh S, Nukiwa T.

Respir Investig. 2015 Nov;53(6):271-8. doi: 10.1016/j.resinv.2015.04.005. Epub 2015 Aug 4.

PMID:
26521104
29.

Efficacy of Nintedanib in Idiopathic Pulmonary Fibrosis across Prespecified Subgroups in INPULSIS.

Costabel U, Inoue Y, Richeldi L, Collard HR, Tschoepe I, Stowasser S, Azuma A.

Am J Respir Crit Care Med. 2016 Jan 15;193(2):178-85. doi: 10.1164/rccm.201503-0562OC.

PMID:
26393389
30.

Nintedanib: evidence for its therapeutic potential in idiopathic pulmonary fibrosis.

Inomata M, Nishioka Y, Azuma A.

Core Evid. 2015 Aug 27;10:89-98. doi: 10.2147/CE.S82905. eCollection 2015. Review.

31.

All-case post-marketing surveillance of 1371 patients treated with pirfenidone for idiopathic pulmonary fibrosis.

Ogura T, Azuma A, Inoue Y, Taniguchi H, Chida K, Bando M, Niimi Y, Kakutani S, Suga M, Sugiyama Y, Kudoh S, Nukiwa T.

Respir Investig. 2015 Sep;53(5):232-41. doi: 10.1016/j.resinv.2015.06.001. Epub 2015 Aug 17.

PMID:
26344613
32.

An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis. An Update of the 2011 Clinical Practice Guideline.

Raghu G, Rochwerg B, Zhang Y, Garcia CA, Azuma A, Behr J, Brozek JL, Collard HR, Cunningham W, Homma S, Johkoh T, Martinez FJ, Myers J, Protzko SL, Richeldi L, Rind D, Selman M, Theodore A, Wells AU, Hoogsteden H, Schünemann HJ; American Thoracic Society; European Respiratory society; Japanese Respiratory Society; Latin American Thoracic Association.

Am J Respir Crit Care Med. 2015 Jul 15;192(2):e3-19. doi: 10.1164/rccm.201506-1063ST. Erratum in: Am J Respir Crit Care Med. 2015 Sep 1;192(5):644. Dosage error in article text.

PMID:
26177183
33.

Evaluation of microelement contents in Clethra barbinervis as food for human and animals in contrasting geological areas.

Azuma AK, Tomioka R, Takenaka C.

Environ Geochem Health. 2016 Apr;38(2):437-48. doi: 10.1007/s10653-015-9731-y. Epub 2015 Jun 29.

PMID:
26119806
34.

Nintedanib modulates surfactant protein-D expression in A549 human lung epithelial cells via the c-Jun N-terminal kinase-activator protein-1 pathway.

Kamio K, Usuki J, Azuma A, Matsuda K, Ishii T, Inomata M, Hayashi H, Kokuho N, Fujita K, Saito Y, Miya T, Gemma A.

Pulm Pharmacol Ther. 2015 Jun;32:29-36. doi: 10.1016/j.pupt.2015.03.001. Epub 2015 Apr 2.

PMID:
25843005
35.

A prospective survey of idiopathic interstitial pneumonias in a web registry in Japan.

Bando M, Sugiyama Y, Azuma A, Ebina M, Taniguchi H, Taguchi Y, Takahashi H, Homma S, Nukiwa T, Kudoh S.

Respir Investig. 2015 Mar;53(2):51-9. doi: 10.1016/j.resinv.2014.11.001. Epub 2014 Dec 4.

PMID:
25745849
36.

Reconsideration of discrepancies between clinical and histopathological features in acute eosinophilic pneumonia.

Mochimaru H, Fukuda Y, Azuma A, Osanai K, Saito Y, Mochimaru T, Gemma A.

Sarcoidosis Vasc Diffuse Lung Dis. 2015 Jan 5;31(4):325-35.

PMID:
25591144
37.

Searching hidden truth behind clinical trials.

Azuma A.

Respir Investig. 2015 Jan;53(1):1. doi: 10.1016/j.resinv.2014.12.001. No abstract available.

38.

Safety and pharmacokinetics of nintedanib and pirfenidone in idiopathic pulmonary fibrosis.

Ogura T, Taniguchi H, Azuma A, Inoue Y, Kondoh Y, Hasegawa Y, Bando M, Abe S, Mochizuki Y, Chida K, Klüglich M, Fujimoto T, Okazaki K, Tadayasu Y, Sakamoto W, Sugiyama Y.

Eur Respir J. 2015 May;45(5):1382-92. doi: 10.1183/09031936.00198013. Epub 2014 Dec 10.

39.

Clinical experience with pirfenidone in five patients with scleroderma-related interstitial lung disease.

Miura Y, Saito T, Fujita K, Tsunoda Y, Tanaka T, Takoi H, Yatagai Y, Rin S, Sekine A, Hayashihara K, Nei T, Azuma A.

Sarcoidosis Vasc Diffuse Lung Dis. 2014 Oct 20;31(3):235-8.

PMID:
25363224
40.

Diagnostic Values For Club Cell Secretory Protein (CC16) in Serum of Patients of Combined Pulmonary Fibrosis and Emphysema.

Kokuho N, Ishii T, Kamio K, Hayashi H, Kurahara M, Hattori K, Motegi T, Azuma A, Gemma A, Kida K.

COPD. 2015 Aug;12(4):347-54. doi: 10.3109/15412555.2014.948994.

PMID:
25244495
41.
42.

Effects of a vigorous gait on mechanical work and oxygen uptake during treadmill walking.

Azuma A.

Percept Mot Skills. 2014 Aug;119(1):6-19. doi: 10.2466/06.26.PMS.119c11z4. Epub 2014 Jun 3.

PMID:
25153734
43.

An autopsy study of combined pulmonary fibrosis and emphysema: correlations among clinical, radiological, and pathological features.

Inomata M, Ikushima S, Awano N, Kondoh K, Satake K, Masuo M, Kusunoki Y, Moriya A, Kamiya H, Ando T, Yanagawa N, Kumasaka T, Ogura T, Sakai F, Azuma A, Gemma A, Takemura T.

BMC Pulm Med. 2014 Jun 28;14:104. doi: 10.1186/1471-2466-14-104.

44.

Clinical features, anti-cancer treatments and outcomes of lung cancer patients with combined pulmonary fibrosis and emphysema.

Minegishi Y, Kokuho N, Miura Y, Matsumoto M, Miyanaga A, Noro R, Saito Y, Seike M, Kubota K, Azuma A, Kida K, Gemma A.

Lung Cancer. 2014 Aug;85(2):258-63. doi: 10.1016/j.lungcan.2014.05.016. Epub 2014 May 22.

PMID:
24894326
45.

Double-blind controlled trial of lecithinized superoxide dismutase in patients with idiopathic interstitial pneumonia - short term evaluation of safety and tolerability.

Kamio K, Azuma A, Ohta K, Sugiyama Y, Nukiwa T, Kudoh S, Mizushima T.

BMC Pulm Med. 2014 May 17;14:86. doi: 10.1186/1471-2466-14-86.

46.

Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis.

Richeldi L, du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U, Cottin V, Flaherty KR, Hansell DM, Inoue Y, Kim DS, Kolb M, Nicholson AG, Noble PW, Selman M, Taniguchi H, Brun M, Le Maulf F, Girard M, Stowasser S, Schlenker-Herceg R, Disse B, Collard HR; INPULSIS Trial Investigators.

N Engl J Med. 2014 May 29;370(22):2071-82. doi: 10.1056/NEJMoa1402584. Epub 2014 May 18. Erratum in: N Engl J Med. 2015 Aug 20;373(8):782.

47.

Ameliorative effect of mepenzolate bromide against pulmonary fibrosis.

Kurotsu S, Tanaka K, Niino T, Asano T, Sugizaki T, Azuma A, Suzuki H, Mizushima T.

J Pharmacol Exp Ther. 2014 Jul;350(1):79-88. doi: 10.1124/jpet.114.213009. Epub 2014 Apr 25.

48.

The WASOG Sarcoidosis Organ Assessment Instrument: An update of a previous clinical tool.

Judson MA, Costabel U, Drent M, Wells A, Maier L, Koth L, Shigemitsu H, Culver DA, Gelfand J, Valeyre D, Sweiss N, Crouser E, Morgenthau AS, Lower EE, Azuma A, Ishihara M, Morimoto S, Tetsuo Yamaguchi T, Shijubo N, Grutters JC, Rosenbach M, Li HP, Rottoli P, Inoue Y, Prasse A, Baughman RP, Organ Assessment Instrument Investigators TW.

Sarcoidosis Vasc Diffuse Lung Dis. 2014 Apr 18;31(1):19-27.

PMID:
24751450
49.

Pirfenidone inhibits fibrocyte accumulation in the lungs in bleomycin-induced murine pulmonary fibrosis.

Inomata M, Kamio K, Azuma A, Matsuda K, Kokuho N, Miura Y, Hayashi H, Nei T, Fujita K, Saito Y, Gemma A.

Respir Res. 2014 Feb 8;15:16. doi: 10.1186/1465-9921-15-16.

50.

Altered cerebellum development and dopamine distribution in a rat genetic model with congenital hypothyroidism.

Shimokawa N, Yousefi B, Morioka S, Yamaguchi S, Ohsawa A, Hayashi H, Azuma A, Mizuno H, Kasagi M, Masuda H, Jingu H, Furudate SI, Haijima A, Takatsuru Y, Iwasaki T, Umezu M, Koibuchi N.

J Neuroendocrinol. 2014 Mar;26(3):164-75. doi: 10.1111/jne.12135.

PMID:
24460919

Supplemental Content

Support Center